IDT Australia Limited (IDT.AX)
ASX · AUD · Healthcare · Drug Manufacturers - Specialty & Generic
A$0.044 (+10.00%) as of
Key statistics
- Market cap
- 18.91M
- Forward P/E
- 4.40
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0300 – 0.0620
- Beta
- 0.93
- Revenue (TTM)
- 20.38M
- Profit margin
- -13.33%
- Volume
- 301.61k
About IDT Australia Limited
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers integrated services, including development, analytical testing, clinical packaging; and microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides formulation and manufacture of speciality orals (medicinal cannabis) and advanced therapies; psychedelics and medicinal cannabis; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the company provides contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Boronia, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.